Products Epcoritamab
Epcoritamab Phase 1 Recruiting 💤 Quiet Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Jun 16, 2025 → Dec 31, 2026
About Epcoritamab Epcoritamab is a phase 1 stage product being developed by AbbVie for Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06672705. Target conditions include Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder.
Clinical Trials (8) NCT ID Phase Status Start Completion Indication NCT05692050 Pre-clinical Completed — — Lymphoma NCT05733650 Pre-clinical Completed — — Large B-cell Lymphoma NCT06796998 Phase 2 Recruiting Oct 13, 2025 Apr 15, 2031 Marginal Zone Lymphoma NCT06931652 Phase 2 Recruiting Sep 22, 2025 Jan 1, 2030 Primary CNS Lymphoma (PCNSL) NCT06672705 Phase 1 Recruiting Jun 16, 2025 Dec 31, 2026 Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder NCT05206357 Phase 1 Active Oct 4, 2022 Nov 1, 2028 Non-hodgkin Lymphoma NCT05451810 Phase 2 Active Aug 17, 2022 Mar 1, 2027 Diffuse Large B-Cell Lymphoma NCT03625037 Phase 1/2 Active Jun 26, 2018 Jan 1, 2029 DLBCL
Competing Products 20 competing products in Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
See all competitors Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2 Epcoritamab + Ibrutinib AbbVie Phase 1/2
Other Products from AbbVie